Molecular profiles of small cell lung cancer subtypes: therapeutic implications
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Molecular profiles of small cell lung cancer subtypes: therapeutic implications
Authors
Keywords
small cell lung cancer, heterogeneity, neuroendocrine, molecular profile
Journal
Molecular Therapy-Oncolytics
Volume 20, Issue -, Pages 470-483
Publisher
Elsevier BV
Online
2021-02-07
DOI
10.1016/j.omto.2021.02.004
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Safety and patient-reported outcomes of atezolizumab, carboplatin, and etoposide in extensive-stage small-cell lung cancer (IMpower133): a randomized phase I/III trial
- (2020) A.S. Mansfield et al. ANNALS OF ONCOLOGY
- Cancer statistics, 2020
- (2020) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- MYC, MYCL, and MYCN as therapeutic targets in lung cancer
- (2020) Daniel Massó-Vallés et al. EXPERT OPINION ON THERAPEUTIC TARGETS
- Immunotherapeutic approaches for small-cell lung cancer
- (2020) Wade T. Iams et al. Nature Reviews Clinical Oncology
- Comparative expression analysis in small cell lung carcinoma reveals neuroendocrine pattern change in primary tumor versus lymph node metastases
- (2020) Zoltan Lohinai et al. Translational Lung Cancer Research
- Pembrolizumab or Placebo Plus Etoposide and Platinum as First-Line Therapy for Extensive-Stage Small-Cell Lung Cancer: Randomized, Double-Blind, Phase III KEYNOTE-604 Study
- (2020) Charles M. Rudin et al. JOURNAL OF CLINICAL ONCOLOGY
- Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trial
- (2020) José Trigo et al. LANCET ONCOLOGY
- Targeted Therapies and Biomarkers in Small Cell Lung Cancer
- (2020) Hirokazu Taniguchi et al. Frontiers in Oncology
- NOTCH Your Usual Suspect: MYC Charged with Controlling Neuroendocrine Cell-Fate in Small Cell Lung Cancer
- (2020) Jin Ng et al. CANCER CELL
- Neuroendocrine subtypes of small cell lung cancer differ in terms of immune microenvironment and checkpoint molecule distribution
- (2020) David Dora et al. Molecular Oncology
- Mechanisms of Immune-Related Complications in Cancer Patients Treated with Immune Checkpoint Inhibitors
- (2020) David König et al. PHARMACOLOGY
- Advances in Small-Cell Lung Cancer (SCLC) Translational Research
- (2020) Benjamin J. Drapkin et al. Cold Spring Harbor Perspectives in Medicine
- LBA85 REACTION: A phase II study of etoposide and cis/carboplatin with or without pembrolizumab in untreated extensive small cell lung cancer
- (2020) B. Besse et al. ANNALS OF ONCOLOGY
- Small Cell Lung Carcinoma Subtypes Defined by ASCL1, NEUROD1, POU2F3 and YAP1: Comprehensive Immunohistochemical and Histopathologic Characterization
- (2020) Marina K. Baine et al. Journal of Thoracic Oncology
- Targeting NOTCH activation in small cell lung cancer through LSD1 inhibition
- (2019) Arnaud Augert et al. Science Signaling
- LBA1_PRNivolumab (nivo) plus ipilimumab (ipi), nivo, or placebo (pbo) as maintenance therapy in patients (pts) with extensive disease small cell lung cancer (ED-SCLC) after first-line (1L) platinum-based chemotherapy (chemo): Results from the double-blind, randomized phase III CheckMate 451 study
- (2019) T K Owonikoko et al. ANNALS OF ONCOLOGY
- Emerging therapies for non-small cell lung cancer
- (2019) Chao Zhang et al. Journal of Hematology & Oncology
- Analysis of DLL3 and ASCL1 in Surgically Resected Small Cell Lung Cancer (HOT1702)
- (2019) Megumi Furuta et al. ONCOLOGIST
- Future Options of Molecular-Targeted Therapy in Small Cell Lung Cancer
- (2019) Arik Bernard Schulze et al. Cancers
- MYC-Driven Small-Cell Lung Cancer is Metabolically Distinct and Vulnerable to Arginine Depletion
- (2019) Milind D. Chalishazar et al. CLINICAL CANCER RESEARCH
- Recent Advances in Lung Cancer Immunotherapy: Input of T-Cell Epitopes Associated With Impaired Peptide Processing
- (2019) Marine Leclerc et al. Frontiers in Immunology
- Efficacy and Safety of Rovalpituzumab Tesirine in Third-Line and Beyond Patients with DLL3-Expressing, Relapsed/Refractory Small Cell Lung Cancer: Results From the Phase II TRINITY Study
- (2019) Daniel Morgensztern et al. CLINICAL CANCER RESEARCH
- Immunopathogenesis of Immune Checkpoint Inhibitor-Related Adverse Events: Roles of the Intestinal Microbiome and Th17 Cells
- (2019) Ronald Anderson et al. Frontiers in Immunology
- Immunotherapy in small-cell lung cancer: from molecular promises to clinical challenges
- (2019) A. Pavan et al. Journal for ImmunoTherapy of Cancer
- Nivolumab Monotherapy and Nivolumab Plus Ipilimumab in Recurrent Small Cell Lung Cancer: Results From the CheckMate 032 Randomized Cohort
- (2019) Neal E. Ready et al. Journal of Thoracic Oncology
- SCLC, Paraneoplastic Syndromes, and the Immune System
- (2019) Martin Sebastian et al. Journal of Thoracic Oncology
- Randomized Phase II Study of Paclitaxel plus Alisertib versus Paclitaxel plus Placebo as Second-Line Therapy for SCLC: Primary and Correlative Biomarker Analyses
- (2019) Taofeek K. Owonikoko et al. Journal of Thoracic Oncology
- Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial
- (2019) Luis Paz-Ares et al. LANCET
- Technological and Therapeutic Advances in Advanced Small Cell Lung Cancer
- (2019) Lum et al. Cancers
- Immune checkpoint inhibitors in melanoma in the metastatic, neoadjuvant, and adjuvant setting
- (2019) Hugo Herrscher et al. CURRENT OPINION IN ONCOLOGY
- Pembrolizumab After Two or More Lines of Previous Therapy in Patients With Recurrent or Metastatic SCLC: Results From the KEYNOTE-028 and KEYNOTE-158 Studies
- (2019) Hyun Cheol Chung et al. Journal of Thoracic Oncology
- POU2F3 is a master regulator of a tuft cell-like variant of small cell lung cancer
- (2018) Yu-Han Huang et al. GENES & DEVELOPMENT
- A time for YAP1: Tumorigenesis, immunosuppression and targeted therapy
- (2018) Masahiro Shibata et al. INTERNATIONAL JOURNAL OF CANCER
- Randomized, Double-Blind, Phase II Study of Temozolomide in Combination With Either Veliparib or Placebo in Patients With Relapsed-Sensitive or Refractory Small-Cell Lung Cancer
- (2018) M. Catherine Pietanza et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II Study of Maintenance Pembrolizumab in Patients with Extensive-Stage Small Cell Lung Cancer (SCLC)
- (2018) Shirish M. Gadgeel et al. Journal of Thoracic Oncology
- Immune checkpoint inhibitors in urothelial cancer: recent updates and future outlook
- (2018) Dharmesh Gopalakrishnan et al. Therapeutics and Clinical Risk Management
- The Role of Indoleamine-2,3-Dioxygenase in Cancer Development, Diagnostics, and Therapy
- (2018) Lilla Hornyák et al. Frontiers in Immunology
- Managing Patients With Relapsed Small-Cell Lung Cancer
- (2018) Jun Gong et al. Journal of Oncology Practice
- Safety and clinical activity of durvalumab in combination with tremelimumab in extensive disease small-cell lung cancer (ED-SCLC).
- (2018) Daniel C. Cho et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase 2 study of pembrolizumab in advanced small-cell lung cancer (SCLC): KEYNOTE-158.
- (2018) Hyun Cheol Chung et al. JOURNAL OF CLINICAL ONCOLOGY
- Impact of Baseline Steroids on Efficacy of Programmed Cell Death-1 and Programmed Death-Ligand 1 Blockade in Patients With Non–Small-Cell Lung Cancer
- (2018) Kathryn C. Arbour et al. JOURNAL OF CLINICAL ONCOLOGY
- First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer
- (2018) Leora Horn et al. NEW ENGLAND JOURNAL OF MEDICINE
- Intertumoral Heterogeneity in SCLC Is Influenced by the Cell Type of Origin
- (2018) Dian Yang et al. Cancer Discovery
- Crebbp loss drives small cell lung cancer and increases sensitivity to HDAC inhibition
- (2018) Deshui Jia et al. Cancer Discovery
- Tumor mutational burden (TMB) as a biomarker of response to immunotherapy in small cell lung cancer
- (2018) Yanis Boumber Journal of Thoracic Disease
- LBA5Efficacy and safety of nivolumab (nivo) monotherapy versus chemotherapy (chemo) in recurrent small cell lung cancer (SCLC): Results from CheckMate 331
- (2018) M Reck et al. ANNALS OF ONCOLOGY
- Randomized Phase II Trial of Cisplatin and Etoposide in Combination With Veliparib or Placebo for Extensive-Stage Small-Cell Lung Cancer: ECOG-ACRIN 2511 Study
- (2018) Taofeek K. Owonikoko et al. JOURNAL OF CLINICAL ONCOLOGY
- Seneca Valley virus attachment and uncoating mediated by its receptor anthrax toxin receptor 1
- (2018) Lin Cao et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Third-Line Nivolumab Monotherapy in Recurrent SCLC: CheckMate 032
- (2018) Neal Ready et al. Journal of Thoracic Oncology
- Pembrolizumab in Patients With Extensive-Stage Small-Cell Lung Cancer: Results From the Phase Ib KEYNOTE-028 Study
- (2017) Patrick A. Ott et al. JOURNAL OF CLINICAL ONCOLOGY
- Intratumoural heterogeneity generated by Notch signalling promotes small-cell lung cancer
- (2017) Jing Shan Lim et al. NATURE
- Unravelling the biology of SCLC: implications for therapy
- (2017) Joshua K. Sabari et al. Nature Reviews Clinical Oncology
- Reciprocal expression of INSM1 and YAP1 defines subgroups in small cell lung cancer
- (2017) Karen McColl et al. Oncotarget
- Dynamic variations in epithelial-to-mesenchymal transition (EMT), ATM, and SLFN11 govern response to PARP inhibitors and cisplatin in small cell lung cancer
- (2017) C. Allison Stewart et al. Oncotarget
- Prognostic value of smoking status in non-small-cell lung cancer patients treated with immune checkpoint inhibitors: a meta-analysis
- (2017) Jung Han Kim et al. Oncotarget
- Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden
- (2017) Zachary R. Chalmers et al. Genome Medicine
- Progress and prospects of early detection in lung cancer
- (2017) Sean Blandin Knight et al. Open Biology
- Notch signaling triggers the tumor heterogeneity of small cell lung cancer
- (2017) Lydia Meder et al. Journal of Thoracic Disease
- YAP and TAZ modulate cell phenotype in a subset of small cell lung cancer
- (2016) Masafumi Horie et al. CANCER SCIENCE
- Nfib Promotes Metastasis through a Widespread Increase in Chromatin Accessibility
- (2016) Sarah K. Denny et al. CELL
- SCLC–State of the Art and What Does the Future Have in Store?
- (2016) Kathrin Kahnert et al. Clinical Lung Cancer
- Phase III Randomized Trial of Ipilimumab Plus Etoposide and Platinum Versus Placebo Plus Etoposide and Platinum in Extensive-Stage Small-Cell Lung Cancer
- (2016) Martin Reck et al. JOURNAL OF CLINICAL ONCOLOGY
- Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study
- (2016) James C Yao et al. LANCET
- Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial
- (2016) Scott J Antonia et al. LANCET ONCOLOGY
- Aurora-A Kinase: A Potent Oncogene and Target for Cancer Therapy
- (2016) Min Yan et al. MEDICINAL RESEARCH REVIEWS
- Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer
- (2016) Martin Reck et al. NEW ENGLAND JOURNAL OF MEDICINE
- A Randomized Phase II Study of Linsitinib (OSI-906) Versus Topotecan in Patients With Relapsed Small-Cell Lung Cancer
- (2016) Alberto A. Chiappori et al. ONCOLOGIST
- Mutational signatures associated with tobacco smoking in human cancer
- (2016) L. B. Alexandrov et al. SCIENCE
- ASCL1 and NEUROD1 Reveal Heterogeneity in Pulmonary Neuroendocrine Tumors and Regulate Distinct Genetic Programs
- (2016) Mark D. Borromeo et al. Cell Reports
- PD-L1 expression in small cell neuroendocrine carcinomas
- (2015) Anne M. Schultheis et al. EUROPEAN JOURNAL OF CANCER
- Bolstering the Case for Lobectomy in Stages I, II, and IIIA Small-Cell Lung Cancer Using the National Cancer Data Base
- (2015) Susan E. Combs et al. Journal of Thoracic Oncology
- The 2015 World Health Organization Classification of Lung Tumors
- (2015) William D. Travis et al. Journal of Thoracic Oncology
- Safety and activity of alisertib, an investigational aurora kinase A inhibitor, in patients with breast cancer, small-cell lung cancer, non-small-cell lung cancer, head and neck squamous-cell carcinoma, and gastro-oesophageal adenocarcinoma: a five-arm phase 2 study
- (2015) Bohuslav Melichar et al. LANCET ONCOLOGY
- Comprehensive genomic profiles of small cell lung cancer
- (2015) Julie George et al. NATURE
- Epigenetic inactivation of the putative DNA/RNA helicase SLFN11 in human cancer confers resistance to platinum drugs
- (2015) Vanesa Nogales et al. Oncotarget
- From Fly Wings to Targeted Cancer Therapies: A Centennial for Notch Signaling
- (2014) Panagiotis Ntziachristos et al. CANCER CELL
- RE-1 silencing transcription factor (REST): a regulator of neuronal development and neuronal/endocrine function
- (2014) Gerald Thiel et al. CELL AND TISSUE RESEARCH
- Surgery for Small Cell Lung Cancer: A Retrospective Analysis of 243 Patients from Japanese Lung Cancer Registry in 2004
- (2014) Hidefumi Takei et al. Journal of Thoracic Oncology
- NCIC CTG IND.190 Phase I Trial of Dalotuzumab (MK-0646) in Combination with Cisplatin and Etoposide in Extensive-Stage Small-Cell Lung Cancer
- (2014) Peter M. Ellis et al. Journal of Thoracic Oncology
- Small Cell Lung Carcinoma: Staging, Imaging, and Treatment Considerations
- (2014) Brett W. Carter et al. RADIOGRAPHICS
- Selective Tropism of Seneca Valley Virus for Variant Subtype Small Cell Lung Cancer
- (2013) J. T. Poirier et al. JNCI-Journal of the National Cancer Institute
- Fibroblast growth factor receptor 1 (FGFR1) amplification is a potential therapeutic target in small-cell lung cancer
- (2013) Anne M Schultheis et al. MODERN PATHOLOGY
- Carboplatin- or Cisplatin-Based Chemotherapy in First-Line Treatment of Small-Cell Lung Cancer: The COCIS Meta-Analysis of Individual Patient Data
- (2012) Antonio Rossi et al. JOURNAL OF CLINICAL ONCOLOGY
- Comprehensive genomic analysis identifies SOX2 as a frequently amplified gene in small-cell lung cancer
- (2012) Charles M Rudin et al. NATURE GENETICS
- Putative DNA/RNA helicase Schlafen-11 (SLFN11) sensitizes cancer cells to DNA-damaging agents
- (2012) G. Zoppoli et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- A framework for identification of actionable cancer genome dependencies in small cell lung cancer
- (2012) M. L. Sos et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Specific organ metastases and survival in small cell lung cancer
- (2012) KENSUKE NAKAZAWA et al. Oncology Letters
- Proteomic Profiling Identifies Dysregulated Pathways in Small Cell Lung Cancer and Novel Therapeutic Targets Including PARP1
- (2012) Lauren Averett Byers et al. Cancer Discovery
- Characterization of the cell of origin for small cell lung cancer
- (2011) Kwon-Sik Park et al. CELL CYCLE
- History of Small-Cell Lung Cancer
- (2011) Shadi Haddadin et al. Clinical Lung Cancer
- Randomized Phase II Study of Bevacizumab in Combination With Chemotherapy in Previously Untreated Extensive-Stage Small-Cell Lung Cancer: Results From the SALUTE Trial
- (2011) David R. Spigel et al. JOURNAL OF CLINICAL ONCOLOGY
- Lobectomy leads to optimal survival in early-stage small cell lung cancer: A retrospective analysis
- (2011) John M. Varlotto et al. JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY
- Survival outcomes with the use of surgery in limited-stage small cell lung cancer
- (2010) David Schreiber et al. CANCER
- The IASLC Lung Cancer Staging Project: Proposals Regarding the Relevance of TNM in the Pathologic Staging of Small Cell Lung Cancer in the Forthcoming (Seventh) Edition of the TNM Classification for Lung Cancer
- (2010) Eric Vallières et al. Journal of Thoracic Oncology
- Small Cell Lung Cancer: Are We Making Progress?
- (2009) Jonathan E. Dowell et al. AMERICAN JOURNAL OF THE MEDICAL SCIENCES
- The Gut Mucosa as a Site for Induction of Regulatory T-Cells
- (2009) Meir Mizrahi et al. CURRENT PHARMACEUTICAL DESIGN
- A small-cell lung cancer genome with complex signatures of tobacco exposure
- (2009) Erin D. Pleasance et al. NATURE
- Indoleamine 2,3-dioxygenase in T-cell tolerance and tumoral immune escape
- (2008) Jessica B. Katz et al. IMMUNOLOGICAL REVIEWS
- Targeted Disruption of NeuroD, a Proneural Basic Helix-Loop-Helix Factor, Impairs Distal Lung Formation and Neuroendocrine Morphology in the Neonatal Lung
- (2008) Enid R. Neptune et al. JOURNAL OF BIOLOGICAL CHEMISTRY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started